CrystalsFirst

Categories
NEWS

CRYSTALSFIRST AND NEXMR JOIN FORCES TO SUPERCHARGE FRAGMENT-BASED DRUG DISCOVERY

CRYSTALSFIRST AND NEXMR JOIN FORCES TO SUPERCHARGE FRAGMENT-BASED DRUG DISCOVERY

24th July 2023 – CrystalsFirst GmbH, a leading provider of innovative crystallography solutions, and NexMR GmbH, a technology company specializing in high-performance Nuclear Magnetic Resonance (NMR), are thrilled to announce their strategic collaboration. This partnership aims to redefine the field of fragment-based drug discovery by combining CrystalsFirst’s expertise in crystallography and NexMR’s cutting-edge NMR, ultimately providing better solutions for drug discovery.

Fragment-based drug discovery is a powerful approach that enables the identification of high-quality lead compounds with improved drug-like properties. By utilizing small fragments of molecules, researchers can explore a vast chemical space and optimize the fragments to develop highly potent and selective drugs. However, the success of fragment-based drug discovery heavily relies on efficient fragment screening and accurate structural determination of the protein-fragment complexes.

CrystalsFirst has established itself as a pioneer in crystallography, offering leading technologies and services for protein crystallization and structure determination using its proprietary SmartSoak® technology. Their expertise in obtaining high-quality chemical matter has contributed to numerous breakthroughs in drug discovery projects. By partnering with NexMR, a company known for its innovative solutions in fragment screening, the collaboration will combine their respective strengths to tackle the challenges associated with fragment-based drug discovery.

NexMR’s advanced technologies enable rapid and efficient fragment screening, utilizing advanced nuclear magnetic resonance (NMR) techniques. Their unique platform allows for the identification and characterization of fragment hits, facilitating the selection of the most promising candidates for further development. By integrating NexMR’s fragment screening capabilities with CrystalsFirst’s expertise in protein crystallography, researchers will have access to a comprehensive suite of tools and services for fragment-based drug discovery campaigns.

“We are excited to partner with NexMR to enhance our capabilities in hit identification,” said Dr. Serghei Glinca, CEO of CrystalsFirst. “This collaboration allows us to provide our clients with a more holistic approach, combining cutting-edge fragment screening technologies with our world-class protein crystallography expertise. Together, we aim to accelerate the discovery of novel therapeutics.”

“We are delighted to join forces with CrystalsFirst,” added Dr. Félix Torres Hubiche, CEO of NexMR. “By integrating our fragment screening technologies with CrystalsFirst’s exceptional crystallography capabilities, we aim to deliver a streamlined and comprehensive solution for fragment-based drug discovery. This collaboration holds great promise in unlocking new chemical matter for the development of life-changing medicines.”

CrystalsFirst and NexMR are committed to driving innovation and advancing the field of fragment-based drug discovery. Through their collaboration, they aim to empower biopharmaceutical research worldwide with cutting-edge tools, expertise, and services that will accelerate the development of novel therapeutics for a wide range of diseases.

ABOUT CRYSTALSFIRST:

CrystalsFirst GmbH is a leading provider of cutting-edge structural biology solutions, specializing in protein crystallization and structure determination. With a strong focus on innovation, CrystalsFirst offers state-of-the-art technologies, expertise, and services to support drug discovery research. For more information, visit www.crystalsfirst.com.

ABOUT NEXMR:

NexMR GmbH is an innovative technology company dedicated to revolutionizing fragment-based drug discovery. Leveraging advanced nuclear magnetic resonance (NMR) techniques, NexMR provides efficient solutions for fragment screening and lead optimization. Their cutting-edge platform enables researchers to accelerate the development of novel therapeutics. For more information, visit www.nexmr.com.

FOR MEDIA INQUIRIES, PLEASE CONTACT:

CrystalsFirst GmbH

Dr. Serghei Glinca
Email: serghei.glinca@crystalsfirst.com
Phone: +49 40 228683970

NexMR GmbH
Dr. Félix Torres Hubiche
Email: ftorres@nexmr.com
Phone: +41 78 9203719

 

Download press release here.

Categories
NEWS

CRYSTALSFIRST ESTABLISHES PARTNERSHIP WITH AKTTYVA THERAPEUTICS

CRYSTALSFIRST ESTABLISHES PARTNERSHIP WITH AKTTYVA THERAPEUTICS TO SUPPORT AI-POWERED DRUG DISCOVERY PROGRAMS

Hamburg, Germany February 23, 2023 — CrystalsFirst, a leading provider of small-molecule drug discovery services, announced today the signing of a drug discovery service agreement with
Akttyva Therapeutics. Under the terms of the agreement, CrystalsFirst will apply its proprietary high-performance X-ray crystallography and soaking technology platform to provide protein production and structural biology services on novel protein targets selected by Akttyva’s in building its pipeline. Financial details of the agreement were not disclosed.

“CrystalsFirst’s innovative solutions to structural biology and fragment-based drug discovery are valuable components for ramping up our proprietary drug discovery efforts against a selected portfolio of innovative targets,” said Katya Tsaioun, PhD, Co-founder and Board member of Akttyva”. Akttyva’s first target is a small molecule activator of MAP kinase MK2 and CrystalsFirst technology will allow it to strengthen its suite of proprietary assays and build a pipeline of therapeutics to treat conditions associated with vascular leak. Dr. Tsaioun continued, “this partnership will enable Akttyva to expand its pipeline to other novel targets involved in vascular leakage. We look forward to partnering with CrystalsFirst to jump-start Akttyva’s proprietary drug development efforts as we continue to build a robust and explainable AI-assisted platform for drug discovery against unexplored targets underlying unmet needs of patients.”

“We are excited to be selected by Akttyva, a discovery stage biotech company focused on unlocking the full therapeutic potential of the human kinome to develop new treatments,” said Dr. Serghei Glinca, Chief Executive Officer of CrystalsFirst. We look forward to applying our high-quality protein production expertise and SmartSoak® technology to rapidly deliver high-quality hits and leads as part of Akttyva’s structure-first approach to discovering and developing small-molecule modulators of protein targets.”

ABOUT CRYSTALSFIRST

CrystalsFirst’s unique technology platform enables customers and collaboration partners rapid access to high-fidelity chemical matter across different drug targets and binding modalities. The company offers its high-performance screening, protein, and structural biology platform to pharmaceutical and biotechnology companies for small molecule drug discovery. Within the broad fields of structure-based drug discovery and fragment-based lead generation, the application of CrystalsFirst’s proprietary technology SmartSoak® provides rapid structural insights into numerous target interaction modes with atomic resolution. The company’s fast access to the highest resolution structural data and molecular design strategies support medicinal chemistry in the development of candidate molecules in a time- and cost-efficient way.

ABOUT AKTTYVA THERAPEUTICS, INC.

Akttyva Therapeutics is a drug-discovery company with a proprietary National Science Foundation award-winning AI-assisted Discovery Engine which utilizes a human-in-the-loop 360 approach (AIDE-360), fast-docking scoring and unique databases of novel molecules. Its first program is focused on treating vascular leakage in Acute Respiratory Distress Syndrome (ARDS) by direct activation of MK2 MAP kinase and is in late preclinical stage.

CONTACT:

Dr. Serghei Glinca
serghei.glinca@crystalsfirst.com
+49 6421 968814-1

Categories
NEWS

ODYSSEY TO UNLOCK RELEVANT COMPOUNDS

Chemical Space Docking: Odyssey to Unlock Relevant Compounds

Advances in technology have led to a major breakthrough in chemical space exploration. By combining computational and experimental methods, researchers are unlocking the full potential of structure-based drug discovery. One highly regarded approach is Chemical Space Docking, which plays a crucial role in finding promising drug candidates and valuable compounds within vast chemical space. This state-of-the-art method provides a fast and cost-effective way to identify the most relevant compounds, resulting in high hit rates and chemical diversity among hits. [1],[2]

Read more

Thu, 26 Jan 2023, 16:00 CET
Dr. Serghei Glina, CEO CrystalsFirst GmbH & Alexander Neumann, BioSolveIT

Categories
NEWS

Our fragment-to-hit approach that has been published in the Journal of Medicinal Chemistry.

Our fragment-to-hit approach that has been published in the Journal of Medicinal Chemistry.

Fragment-based drug discovery (FBDD) has proven to be an effective method in finding therapeutics for difficult drug targets. We present a cutting-edge approach to identify active molecules in purchasable chemical space. This method begins with four small-molecule fragments that interact with protein kinase A (PKA). A template-based docking screen using Enamine’s REAL Space database was then conducted. Out of 106 selected compounds, 93 were synthesized and 40 showed activity in validation assays, with the most promising having a 13,500-fold increase in affinity. Crystal structures for six of the strongest binders were quickly obtained to confirm their binding mode. With a success-rate of 40%, this novel fragment-to-hit approach was executed in only 9 weeks. The results challenge the standard fragment prescreening methods as the standard filters used in thermal shift assays would have overlooked the initial fragments.


Read more

Categories
NEWS

FRAGMENT-BASED DRUG DISCOVERY — HITTING TARGETS USING THE RIGHT CHEMISTRY AND EXPERTISE ALLIANCES

Fragment-Based Drug Discovery — Hitting Targets Using the Right Chemistry and Expertise Alliances

Fragment-Based Drug Discovery (FBDD) has gained significant attention and importance in recent years as a method for identifying and optimizing hits for drug development. It has led to the development of approved therapeutics and numerous drug candidates, and has enabled the industry to tackle previously considered “undruggable” targets.

FBDD utilizes the benefits of biophysical, biostructural, and biochemical techniques to detect low molecular weight molecules, known as “fragments”, that bind to a target. This approach has several advantages over traditional high-throughput screening, including lower cost, greater chemical diversity, and wider sampling of potential follow-up compounds.

Experts in the field of FBDD will present case studies and the potential of various cutting-edge strategies for successful hit identification and optimization in this talk. Additionally, Dr. Nir London will present how electrophilic fragment screening can speed up the discovery of a new generation of covalent probes for challenging targets. He will also discuss the application of this method for the discovery of the first in-vivo active chemical probe for Pin1 proline isomerase and SARS-CoV-2 main protease.

Several discovery partners will provide key expertise, including 2bind, which offers a comprehensive service package for all types of projects and scientific questions, including fragment libraries, hit identification, hit validation, and biophysical assays for SAR and medicinal chemistry optimization. CrystalsFirst provides a state-of-the-art structural biology platform to unlock chemical matter for pharmaceutical and biotechnology companies in drug discovery. Its unique technology SmartSoak® stabilizes protein crystals for X-ray crystallography, providing rapid access to high-quality co-structures. Oncodesign is an expert in integrated drug discovery services, offering hit to lead optimization starting from identified fragments and full lead optimization with a dedicated multidisciplinary team.

Thu, 13 Oct 2022

Categories
NEWS

UNLOCKING CHEMICAL MATTER ON SCALE

Unlocking chemical matter on scale

Fragment-based drug discovery (FBDD) has become an indispensable resource for medicinal chemists in searching for lead candidates. To effectively evaluate fragments, various biophysical methods are applied using a cascade approach as a pre-screening step before determining protein-ligand interactions. This approach has been found to be more effective than direct crystallographic screening based on research.

The use of X-ray crystallography as a primary fragment screening method has been limited by the lack of robust systems for soaking experiments and the solubility challenges of fragments. One of the major obstacles in crystal soaking is the sensitivity of protein crystals, but this can be overcome with the SmartSoak® technology, which stabilizes protein crystals to create high-performance soaking systems without any need for trial-and-error optimization.

Our case studies highlight the advantages of using crystallographic fragment screening as the primary screening method for hit identification. The resulting structural data can then be used to explore chemical space on a large scale using computational methods.

Read more

Tue, 07 Jul 2020, 17:00 CET (Berlin)
Dr. Serghei Glina, CEO CrystalsFirst GmbH, Marburg, Germany

Subscribe to stay tuned